PURPOSE V600E is the most common activating BRAF mutation in colorectal carcinomas (CRCs). It is a crucial biomarker for patient selection and response to targeted therapy with BRAF V600E inhibitors. Previous studies using immunohistochemistry (IHC) have shown different results. In this study, we evaluated the IHC expression of the mutated BRAF protein in archival material from CRC specimens an...

Colorectal cancer (CRC) is a heterogeneous disease with different genetic and molecular backgrounds, leading to diverse patient prognosis treatment response. Four consensus subtypes (CMS 1–4) have recently been proposed based on transcriptome profiling. A clinically practical immunohistochemistry (IHC) CMS classifier consisting of the four markers FRMD6, ZEB1, HTR2B, CDX2 was then demonstrated....

Mismatch repair defective (MMRd) colorectal carcinoma (CRC) is a distinct molecular phenotype of colorectal cancer, including 12% of sporadic CRC and 3% of Lynch Syndrome. In order to investigate the clinicopathological characteristics of MMRd colorectal carcinoma, and to find the most effective method for preliminary screening, 296 CRC fulfilled revised Bethesda Guideline (RB) were selected fr...

Introduction Colorectal carcinoma (CRC) is one of the most common cancers that involve human body. Young-onset CRC (YO-CRC) or early-onset (EO-CRC) defined as develops before age 50 years, opposed to diagnosed after 50, referred late-onset (LO-CRC). EO-CRC sparsely studied in our population. Therefore, this study, we evaluated clinicopathological parameters and biomarker profile compared them w...

Anti-EGFR therapy is commonly used to treat colorectal cancer (CRC), although only a subset of patients benefit from the treatment. While KRAS mutation predicts non-responsiveness, positive predictive markers are not in clinical practice. We previously showed that immunohistochemistry (IHC)-guided EGFR gene copy number (GCN) analysis may identify CRC patients benefiting from anti-EGFR treatment...